New drug combo targets Hard-to-Treat cancers

NCT ID NCT04866134

Ongoing Disease control Sponsor: Erasca, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two experimental drugs, ERAS-007 and ERAS-601, in people with advanced solid tumors that have not responded to standard treatments. The drugs are taken orally and aim to block signals that help cancer grow. The trial will first find safe doses and then check if the drugs can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ERAS-007 (ERK inhibitor) and ERAS-601 (SHP2 inhibitor)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early-phase trial (Phase 1b/2) with a small number of participants, so the drugs may not prove effective or may have significant side effects. The results may not apply to all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMORS

Contacts and locations

Locations

Mary Crowley Cancer Research

Dallas, Texas, 75251, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute (Florida Cancer Specialists)

Sarasota, Florida, 34232, United States
Sarah Cannon Research Institute (HealthONE)

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute (Tennessee Oncology)

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.